<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8150141</article-id>
    <article-id pub-id-type="pmid">33305308</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btaa935</article-id>
    <article-id pub-id-type="publisher-id">btaa935</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Papers</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Gene Expression</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ECMarker: interpretable machine learning model identifies gene expression biomarkers predicting clinical outcomes and reveals molecular mechanisms of human disease in early stages</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5073-0667</contrib-id>
        <name>
          <surname>Jin</surname>
          <given-names>Ting</given-names>
        </name>
        <aff><institution>Department of Biostatistics and Medical Informatics, University of Wisconsin – Madison</institution>, Madison, WI 53706, <country country="US">USA</country></aff>
        <xref rid="btaa935-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nguyen</surname>
          <given-names>Nam D</given-names>
        </name>
        <aff><institution>Department of Computer Science, Stony Brook University</institution>, Stony Brook, NY 11794, <country country="US">USA</country></aff>
        <xref rid="btaa935-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Talos</surname>
          <given-names>Flaminia</given-names>
        </name>
        <aff><institution>Departments of Pathology and Urology</institution>, Stony Brook, NY 11794, <country country="US">USA</country></aff>
        <aff><institution>Stony Brook Cancer Center, Stony Brook Medicine</institution>, Stony Brook, NY 11794, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9190-3704</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Daifeng</given-names>
        </name>
        <xref rid="btaa935-cor1" ref-type="corresp"/>
        <aff><institution>Department of Biostatistics and Medical Informatics, University of Wisconsin – Madison</institution>, Madison, WI 53706, <country country="US">USA</country></aff>
        <aff><institution>Waisman Center, University of Wisconsin – Madison</institution>, Madison, WI 53705, <country country="US">USA</country></aff>
        <!--daifeng.wang@wisc.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Pier Luigi</surname>
          <given-names>Martelli</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <fn id="btaa935-FM1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
      <corresp id="btaa935-cor1">To whom correspondence should be addressed. <email>daifeng.wang@wisc.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>15</day>
      <month>4</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-12-10">
      <day>10</day>
      <month>12</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>12</month>
      <year>2020</year>
    </pub-date>
    <volume>37</volume>
    <issue>8</issue>
    <fpage>1115</fpage>
    <lpage>1124</lpage>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>11</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>27</day>
        <month>9</month>
        <year>2020</year>
      </date>
      <date date-type="editorial-decision">
        <day>21</day>
        <month>10</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>22</day>
        <month>10</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btaa935.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Gene expression and regulation, a key molecular mechanism driving human disease development, remains elusive, especially at early stages. Integrating the increasing amount of population-level genomic data and understanding gene regulatory mechanisms in disease development are still challenging. Machine learning has emerged to solve this, but many machine learning methods were typically limited to building an accurate prediction model as a ‘black box’, barely providing biological and clinical interpretability from the box.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>To address these challenges, we developed an interpretable and scalable machine learning model, ECMarker, to predict gene expression biomarkers for disease phenotypes and simultaneously reveal underlying regulatory mechanisms. Particularly, ECMarker is built on the integration of semi- and discriminative-restricted Boltzmann machines, a neural network model for classification allowing lateral connections at the input gene layer. This interpretable model is scalable without needing any prior feature selection and enables directly modeling and prioritizing genes and revealing potential gene networks (from lateral connections) for the phenotypes. With application to the gene expression data of non-small-cell lung cancer patients, we found that ECMarker not only achieved a relatively high accuracy for predicting cancer stages but also identified the biomarker genes and gene networks implying the regulatory mechanisms in the lung cancer development. In addition, ECMarker demonstrates clinical interpretability as its prioritized biomarker genes can predict survival rates of early lung cancer patients (<italic toggle="yes">P</italic>-value &lt; 0.005). Finally, we identified a number of drugs currently in clinical use for late stages or other cancers with effects on these early lung cancer biomarkers, suggesting potential novel candidates on early cancer medicine.</p>
      </sec>
      <sec id="s3">
        <title>Availabilityand implementation</title>
        <p>ECMarker is open source as a general-purpose tool at <ext-link xlink:href="https://github.com/daifengwanglab/ECMarker" ext-link-type="uri">https://github.com/daifengwanglab/ECMarker</ext-link>.</p>
      </sec>
      <sec id="s5">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R01AG067025</award-id>
        <award-id>R21CA237955</award-id>
        <award-id>U01MH116492</award-id>
        <award-id>U54HD090256</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Waisman Center</institution>
            <institution-id institution-id-type="DOI">10.13039/100007925</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Human disease development such as cancer is a complex, dynamic process that is fundamentally driven by abnormal molecular mechanisms. However, understanding the cancer mechanisms is still a challenging task, especially during the early cancer development (<xref rid="btaa935-B17" ref-type="bibr">Herbst <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btaa935-B28" ref-type="bibr">Koeffler <italic toggle="yes">et al.</italic>, 1991</xref>). To this end, the tumor/node/metastasis (TNM) system has been widely used to characterize and classify the cancer development into various stages (<xref rid="btaa935-B42" ref-type="bibr">Ludwig and Weinstein, 2005</xref>). The TNM stages were further associated with a number of individual molecular biomarkers and clinical outcomes such as survival rates (<xref rid="btaa935-B42" ref-type="bibr">Ludwig and Weinstein, 2005</xref>). However, with the advancement of whole genome sequencing of numerous human tumors, it became apparent that the molecular profiles of various tumor stages might not necessarily be reflected by the TNM system. Therefore, using systems biology approaches to identify the biomarkers that drive cancers from early to late stages could allow for better understanding of cancer mechanisms and offer new venues for the development of new preventive and therapeutic strategies.</p>
    <p>However, there is a gap in understanding of the molecular biomarkers of early cancer and their underlying mechanisms at a system level. For example, the lung cancer, causing 27% of cancer-related deaths in the USA alone (<xref rid="btaa935-B62" ref-type="bibr">Siegel <italic toggle="yes">et al.</italic>, 2018</xref>), is localized to the lung; neither lymph nodes nor other organs are believed to be affected at the early stage. As the cancer progresses to a more advanced stage, nearby lymph nodes and other organs may be affected (<xref rid="btaa935-B12" ref-type="bibr">Frost <italic toggle="yes">et al.</italic>, 1984</xref>; <xref rid="btaa935-B20" ref-type="bibr">Hu <italic toggle="yes">et al.</italic>, 2008</xref>). This pathological difference suggests that the underlying molecular mechanisms of the early and late stages are different. Also, if cancer is diagnosed at an early stage, such as a localized stage, the five-year survival rate is approximately 50%; this is mostly due to surgical interventions involving lung removal. After the localized stages, survival rates decrease rapidly as cases involving the lymph nodes or other metastatic sites necessitate elaborate treatment strategies (<xref rid="btaa935-B20" ref-type="bibr">Hu <italic toggle="yes">et al.</italic>, 2008</xref>). Nearly 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis (<xref rid="btaa935-B46" ref-type="bibr">Molina <italic toggle="yes">et al.</italic>, 2008</xref>). Thus, although a number of studies have indicated that early localized stages are easier to treat and have better survival rates, the underlying molecular mechanisms remain elusive. Here, we hypothesized that early cancers have different molecular wiring at a system level and that understanding this wiring could reveal new biomarkers and mechanisms of early cancer development. Thus, it is essential to identify the specific biomarkers of early cancer to understand the molecular mechanisms driving cancer development; this would enhance early cancer diagnosis and therefore improve survival rates.</p>
    <p>Detecting early cancer biomarkers, however, involves the inherent challenges of relating the complex, multi-dimensional molecular processing that occurs in organs and tissues during early-stage cancer to observable clinical phenotypes in human patients. In particular, differential, temporal and spatial gene expression during early cancer result from disruptions in the complex, dynamic and multi-gene process that tightly regulates and controls the developmental integrity of organs and tissues. These temporal and spatial gene expression dynamics are fundamentally controlled by a variety of molecules called gene regulatory factors, including transcription factors (TFs) and non-coding RNAs. These factors cooperate in a gene regulatory network (GRN) to carry out correct developmental functions on a genome scale (<xref rid="btaa935-B23" ref-type="bibr">Iyer <italic toggle="yes">et al.</italic>, 2017</xref>). The nodes of a GRN are genes, and the edges of a GRN connect regulatory factors to their target genes. Disruption of the cooperation between genes and regulatory factors in a GRN can give rise to abnormal gene expression, such as that which is present in diseases such as cancer. Therefore, a fundamental challenge for uncovering early cancer mechanisms is that of understanding the gene regulatory mechanisms, especially GRNs, controlling the changes in gene expression across cancer stages.</p>
    <p>The collection of next-generation sequencing (NGS) data from large cohorts such as TCGA (<xref rid="btaa935-B38" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2018a</xref>, <xref rid="btaa935-B39" ref-type="bibr">b</xref>) provides measurements across multi-omics, including transcriptomics and epigenomics. This allows for studies of temporal dynamics in gene expression and regulation during cancer development and also for the systematic identification of stage-specific cancer biomarkers. Progress has been made in identification of some stage-specific molecular biomarkers of lung cancer, but systematic genome-wide analyses for identification of all potential early-stage biomarkers with predictive value for disease outcome are limited. For example, dysregulations in the epidermal growth factor receptor EGFR, associated with sensitivity of lung cancers to the tyrosine kinase inhibitor gefitinib (Iressa) (<xref rid="btaa935-B51" ref-type="bibr">Pao <italic toggle="yes">et al.</italic>, 2004</xref>), echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) are frequently involved in oncogenic transformation (<xref rid="btaa935-B37" ref-type="bibr">Lindeman <italic toggle="yes">et al.</italic>, 2013</xref>). In addition, v-raf murine sarcoma viral oncogene homologue B1 (BRAF) is a driver mutation gene in lung adenocarcinoma (<xref rid="btaa935-B50" ref-type="bibr">Paik <italic toggle="yes">et al.</italic>, 2011</xref>). Although a challenging task, finding novel ways to integrate the large-scale data provided by human tumors would enable the discovery of genome-wide early cancer biomarkers and underlying GRNs.</p>
    <p>Traditionally, correlation-based models have been used to select biomarker genes involved in cancer development; e.g. 62 genes were uncovered in this way to distinguish between the early and late stages of clear cell renal cell carcinoma (ccRCC) (<xref rid="btaa935-B24" ref-type="bibr">Jagga and Gupta, 2014</xref>; Rahimi and G<bold>ö</bold>nen, <xref rid="btaa935-B55" ref-type="bibr">2018</xref>). However, correlation-based models only reveal linear relationships, whereas cancer development is a complex, non-linear process. Thus, machine learning has emerged as a powerful tool to predict biomarkers for various cancer features related to clinical presentation and staging; this tool has been found to be of great help in the diagnosis and treatment of various diseases (<xref rid="btaa935-B34" ref-type="bibr">Libbrecht and Noble, 2015</xref>). For example, <xref rid="btaa935-B63" ref-type="bibr">Statnikov et al., (2008)</xref> applied random forests (RFs) and support vector machines (SVMs) to microarray data in order to aid in cancer diagnosis. <xref rid="btaa935-B72" ref-type="bibr">Xiao et al., (2018)</xref> constructed a multi-model ensemble approach to predict cancer in both normal conditions and tumor conditions. However, none of these studies revealed novel cancer mechanistic insights; these studies were limited to building an accurate classification model as a ‘black box’ but lacked any biological or clinical interpretability from the box. In addition, the biological datasets especially for genomics have the challenging of ‘curse of dimensionality’ (<xref rid="btaa935-B7" ref-type="bibr">Clarke <italic toggle="yes">et al.</italic>, 2008</xref>); e.g. variables (e.g. genes) are much more than samples. To solve this, many machine learning methods applied prior feature selections to reduce the dimensionality, which however likely miss potentially important information at the system level.</p>
    <p>To address these challenges, we designed a novel, interpretable machine learning approach, ECMarker, that can be used to discover gene expression biomarkers for the early disease stages, and simultaneously unravel the underlying molecular mechanisms in the ‘black box’ such as gene regulatory networks (GRNs). In particular, ECMarker is built on a neural network model, semi-restricted Boltzmann machine (SRBM) allowing lateral connections at the input gene layer for classifying disease phenotypes using population-level gene expression data. The SRBM model (<xref rid="btaa935-B49" ref-type="bibr">Osindero and Hinton, 2007</xref>) has been used in non-biological contexts (e.g. computer vision, image classification) enabling modeling intra-connections among input variables (e.g. image patches). Based on the neural network connectivity, ECMarker further enables prioritizing genes and revealing the underlying gene network (from lateral connections) for predicting phenotypes. Compared to other methods, ECMarker is an interpretable model aiming to reveal underlying molecular mechanisms (e.g. gene regulation) while predicting phenotype. Many existing machine learning models still aim to learn a ‘black box’ with high accuracy, which is not straightforward to provide any biological insights as described above. ECMarker, instead, was designed to achieve all ‘interpretability’, ‘accuracy’ and ‘scalability’ via (i) using the lateral connections at the visible layer (i.e. genes) to reveal gene networks, (ii) simultaneously trying to achieve relatively high accuracy of classifying disease stages and (iii) inputting all genes and prioritizing genes by implicit feature selection. With applications to cancer genomic data, the prioritized genes and networks for early/late cancer stages revealed potential cancer stage-specific gene biomarkers and GRNs. Furthermore, we found the drugs that have significant effects on the ECMarker biomarkers for uncovering novel genomic medicine to early cancer development.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 ECMarker, an interpretable machine learning model to identify gene expression biomarkers and reveal underlying molecular mechanisms for disease phenotypes and clinical outcomes</title>
      <p>ECMarker consists of three major components (<xref rid="btaa935-F1" ref-type="fig">Fig. 1</xref>) including (i) a neural network model, integrating the semi-restricted Boltzmann machine (SRBM) (<xref rid="btaa935-B49" ref-type="bibr">Osindero and Hinton, 2007</xref>) with the Discriminative restricted Boltzmann machine (DRBM) (<xref rid="btaa935-B30" ref-type="bibr">Larochelle and Bengio, 2008</xref>) for classifying disease phenotypes from the gene expression data at the population level; (ii) the prioritization of gene expression biomarkers for each phenotype using the integrated gradient method based on the neural network connectivity, and identification of a gene network using the lateral connections at the input layer; (iii) the functional and survival analyses of biomarker genes and networks for revealing underlying molecular mechanisms in the disease phenotypes (biological interpretability) and predicting clinical outcomes (clinical interpretability). We elaborated each component as follows.</p>
      <fig position="float" id="btaa935-F1">
        <label>Fig. 1.</label>
        <caption>
          <p>ECMarker, an interpretable machine learning framework for the identification of gene expression biomarkers of cancer stages and the prediction of clinical outcomes. ECMarker is a hierarchical neural network approach integrating semi- and discriminative-restricted Boltzmann machine models, to input the gene expression data of patients for predicting their disease phenotypes; e.g. early and late cancer stages. In particular, the ECMarker classification model consists of three layers: (1) the input gene layer <bold><italic toggle="yes">v</italic></bold>, (2) the hidden layer <bold><italic toggle="yes">h</italic></bold> and (3) the output phenotype layer <bold><italic toggle="yes">y</italic></bold>; e.g. early versus late cancer stages. The lateral connections at the input gene layer enable identifying a gene network providing potential mechanistic insights for disease phenotypes. Thus, in addition to the phenotype prediction, ECMarker is also biologically and clinically interpretable for (<bold>A</bold>) identifying the gene expression biomarkers and gene networks for phenotypes (e.g. early and late stages); (<bold>B</bold>) revealing the associated biological functions and pathways for each phenotype; (<bold>C</bold>) predicting clinical outcomes such as survival rates, especially for early cancer patients; and (<bold>D</bold>) discovering novel drugs potentially affecting early cancer. Red and blue represent early and late stages, respectively</p>
        </caption>
        <graphic xlink:href="btaa935f1" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>2.2 The ECMarker classification model</title>
      <p>The standard restricted Boltzmann machine (RBM) is an energy-based model that uses a layer of <inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mi>n</mml:mi></mml:math></inline-formula> hidden units to model a distribution over <inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mi>m</mml:mi></mml:math></inline-formula> visible units in the other layer (<xref rid="btaa935-B18" ref-type="bibr">Hinton and Salakhutdinov, 2006</xref>). The connections between the two layers (i.e. visible layer to hidden layer) and all visible and hidden units form a bipartite graph. Thus, the connections within a layer (e.g. a visible unit to another visible unit) are prohibited. Also, the standard RBM typically takes binary values; i.e. <inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>0,1</mml:mn><mml:msup><mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> and <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mi mathvariant="normal">h</mml:mi><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>0,1</mml:mn><mml:msup><mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, and is often trained by the input distributions only. In the ECMarker, we have extended the RBM, based on the semi-restricted Boltzmann machine (SRBM) (<xref rid="btaa935-B49" ref-type="bibr">Osindero and Hinton, 2007</xref>) and the Discriminative RBM (DRBM) (<xref rid="btaa935-B30" ref-type="bibr">Larochelle and Bengio, 2008</xref>) for enabling (i) classification, (ii) inputting continuous values of visible units (e.g. gene expression) and (iii) modeling the gene relationships (i.e. a network) as follows. First, ECMarker inputs the expression profiles of <italic toggle="yes">m</italic> genes as <italic toggle="yes">m</italic> visible nodes <inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>. Second, the hidden layer in the ECMarker consists of the binary variables <inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mn>0,1</mml:mn><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, where <italic toggle="yes">n</italic> is number of hidden nodes. Finally, the output layer <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mfenced open="{" close="}" separators="|"><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> consists of all <italic toggle="yes">K</italic> phenotypes to predict. The improvements of the ECMarker classification model include:
</p>
      <list list-type="order">
        <list-item>
          <p>To deal with the real-valued gene expression data, we replaced the binary visible units in the RBM by linear units with independent Gaussian noises. To simplify calculation, we used the Gaussian noise <sub><bold>∼</bold></sub><inline-formula id="IE8"><mml:math id="IM8" display="inline" overflow="scroll"><mml:mi mathvariant="script">N</mml:mi><mml:mo>(</mml:mo><mml:mn>0,1</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula> and transformed the input data before training; i.e. standardizing features by removing the mean and scaling to unit variance.</p>
        </list-item>
        <list-item>
          <p>We added an output layer <inline-formula id="IE9"><mml:math id="IM9" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mfenced open="{" close="}" separators="|"><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> with discretized values modeling <italic toggle="yes">K</italic> phenotypes (e.g. <italic toggle="yes">K</italic>=2, early versus late disease stages) on the top of the hidden layer, and then used a joint distribution <inline-formula id="IE10"><mml:math id="IM10" display="inline" overflow="scroll"><mml:mrow><mml:munder><mml:mo stretchy="false">∏</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:mfenced><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">train</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> over the training dataset <inline-formula id="IE11"><mml:math id="IM11" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">train</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> of the input <inline-formula id="IE12"><mml:math id="IM12" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> (e.g. <italic toggle="yes">m</italic> gene expression values) and associated phenotype <inline-formula id="IE13"><mml:math id="IM13" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">y</mml:mi></mml:math></inline-formula> for classification.</p>
        </list-item>
        <list-item>
          <p>We allowed lateral connections among the visible units as SRBM did for modeling a network linking genes while predicting phenotypes.</p>
        </list-item>
      </list>
      <p>In particular, the probability distribution represented by the ECMarker classification model with parameters <inline-formula id="IE14"><mml:math id="IM14" display="inline" overflow="scroll"><mml:mo>Θ</mml:mo></mml:math></inline-formula> is <inline-formula id="IE15"><mml:math id="IM15" display="inline" overflow="scroll"><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>|</mml:mo><mml:mo>Θ</mml:mo><mml:mo>)</mml:mo><mml:mo>∝</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>E</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula>, where <inline-formula id="IE16"><mml:math id="IM16" display="inline" overflow="scroll"><mml:mi>E</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo><mml:mo>)</mml:mo></mml:math></inline-formula> is the energy function defined b<italic toggle="yes"><sc>y</sc></italic>
 <disp-formula id="E1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>E</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>-</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>W</mml:mi><mml:mi>v</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">a</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>v</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">b</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>h</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>y</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">h</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>U</mml:mi><mml:mi>y</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>L</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>with that <inline-formula id="IE17"><mml:math id="IM17" display="inline" overflow="scroll"><mml:mo>Θ</mml:mo><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">c</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">U</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">L</mml:mi><mml:mo>}</mml:mo></mml:math></inline-formula> represents the model parameters. Note that the first three terms in the energy function are the same in the standard RBMs in which <inline-formula id="IE18"><mml:math id="IM18" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msup><mml:mi mathvariant="normal"> </mml:mi></mml:math></inline-formula>models the weight connections between <italic toggle="yes">m</italic> visible units and <italic toggle="yes">n</italic> hidden nodes, <inline-formula id="IE19"><mml:math id="IM19" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> is the bias of visible input units, and <inline-formula id="IE20"><mml:math id="IM20" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> is the bias of hidden nodes. The fourth and fifth terms model the contributions from the phenotype <inline-formula id="IE21"><mml:math id="IM21" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">y</mml:mi></mml:math></inline-formula> in which <inline-formula id="IE22"><mml:math id="IM22" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">U</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>K</mml:mi></mml:mrow></mml:msup><mml:mi mathvariant="normal"> </mml:mi></mml:math></inline-formula>models the weight connections between target and hidden layers, and <inline-formula id="IE23"><mml:math id="IM23" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">c</mml:mi><mml:mo>∈</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> is the bias of target. The last term, a quadratic term of visible units <inline-formula id="IE24"><mml:math id="IM24" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">v</mml:mi></mml:math></inline-formula> models two aspects contributing the energy: (i) the lateral connections among genes where <inline-formula id="IE25"><mml:math id="IM25" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">L</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>×</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> encodes the gene-gene relationships (i.e. adjacency matrix of a gene network) and (ii) the Gaussian units of gene expression inputs. We combined these two aspects in one term because they did not affect the calculation of log-likelihood gradient in training.</p>
      <p>The conditional probability distribution of <italic toggle="yes">i</italic>th visible unit, <inline-formula id="IE26"><mml:math id="IM26" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> with real continuous value given the hidden units and other visible units (according to lateral connections among genes), is given by:
<disp-formula id="E2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mtext>|</mml:mtext><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:mi>Θ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">h</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>:</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow><mml:mrow><mml:mo>:</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula id="IE27"><mml:math id="IM27" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">L</mml:mi></mml:math></inline-formula> is a hollow matrix whose diagonal elements are all equal to zero, and <inline-formula id="IE38"><mml:math id="IM28" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>:</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mtext>  </mml:mtext><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow><mml:mrow><mml:mo>:</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the <inline-formula id="IE28"><mml:math id="IM29" display="inline" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>th columns of matrices <inline-formula id="IE29"><mml:math id="IM30" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">W</mml:mi></mml:math></inline-formula> and <inline-formula id="IE30"><mml:math id="IM31" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">L</mml:mi></mml:math></inline-formula> respectively.</p>
      <p>The conditional probability distribution of the output units (of binary values) given the hidden units is as follows:
<disp-formula id="E3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>p</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">h</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi mathvariant="bold-italic">U</mml:mi></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where <inline-formula id="IE31"><mml:math id="IM32" display="inline" overflow="scroll"><mml:mo>σ</mml:mo><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> is the logistic sigmoid function.</p>
      <p>The hidden units capture predictive information from both the visible inputs and the output classes. Thus, the conditional probability distribution of the hidden units (of binary values<bold>)</bold> given the visible inputs and output classes has the following form:
<disp-formula id="E4"><label>(4)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>p</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">h</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">Wv</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic">Uy</mml:mi></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
      <p>In training, because only <inline-formula id="IE32"><mml:math id="IM33" display="inline" overflow="scroll"><mml:mi>v</mml:mi></mml:math></inline-formula> and<inline-formula id="IE33"><mml:math id="IM34" display="inline" overflow="scroll"><mml:mi mathvariant="normal"> </mml:mi><mml:mi>y</mml:mi></mml:math></inline-formula> are observed, we calculated the marginal distribution represented by the model:
<disp-formula id="E5"><mml:math id="M5" display="block" overflow="scroll"><mml:mi>p</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced><mml:mo>∝</mml:mo><mml:mrow><mml:munder><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>E</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math></disp-formula>where <inline-formula id="IE34"><mml:math id="IM35" display="inline" overflow="scroll"><mml:mi>F</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo><mml:mo>)</mml:mo></mml:math></inline-formula> is the free energy function defined by <inline-formula id="IE56"><mml:math id="IM36" display="inline" overflow="scroll"><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>;</mml:mo><mml:mi>Θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mtext>log</mml:mtext><mml:mstyle displaystyle="true"><mml:msub><mml:mo>∑</mml:mo><mml:mi>h</mml:mi></mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mo>;</mml:mo><mml:mi>Θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:math></inline-formula>.</p>
      <p>With the energy function aforementioned, the free energy can be further derived as follows:
<disp-formula id="E6"><label>(5)</label><mml:math id="M6" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">a</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>v</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>y</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>L</mml:mi><mml:mi>v</mml:mi><mml:mo>-</mml:mo><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mi mathvariant="normal">log</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">U</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where <inline-formula id="IE35"><mml:math id="IM37" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula id="IE36"><mml:math id="IM38" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">U</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula> are the <inline-formula id="IE67"><mml:math id="IM39" display="inline" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>th rows of matrices <inline-formula id="IE68"><mml:math id="IM40" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">W</mml:mi></mml:math></inline-formula> and <inline-formula id="IE39"><mml:math id="IM41" display="inline" overflow="scroll"><mml:mi mathvariant="bold-italic">L</mml:mi></mml:math></inline-formula> respectively. Furthermore, to address the ‘curse of dimensionality’ problem (i.e. features/genes are much more than samples) in genomic datasets, we trained our classification model with an <inline-formula id="IE40"><mml:math id="IM42" display="inline" overflow="scroll"><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:math></inline-formula> regularization. The <inline-formula id="IE41"><mml:math id="IM43" display="inline" overflow="scroll"><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:math></inline-formula> term, <inline-formula id="IE42"><mml:math id="IM44" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mfenced open="∥" close="∥" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, which acts on the weight connections between the visible input layer and hidden layer, and also serves as an implicit feature selection method to automatically selecting prominent genes responsible for hidden units which models the distribution over visible input units (i.e. genes). This also enables us to add more hidden units to increase the learning capacity without being overfitted. Thus, we introduced the following loss function minimization during the model training:
<disp-formula id="E7"><label>(6)</label><mml:math id="M7" display="block" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msup><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>∈</mml:mo><mml:mi mathvariant="italic">arg</mml:mi><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow></mml:munder><mml:mo>-</mml:mo><mml:mi mathvariant="italic">log</mml:mi><mml:mo> </mml:mo><mml:mi>p</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>;</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mfenced open="∥" close="∥" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
      <p>The data negative log-likelihood gradient is then:
<disp-formula id="E8"><mml:math id="M8" display="block" overflow="scroll"><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfrac><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">og</mml:mi><mml:mi>p</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfrac><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mrow><mml:munder><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:munder><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfrac><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:math></disp-formula>where <inline-formula id="IE43"><mml:math id="IM45" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></inline-formula> are generated examples from the current model’s distribution <inline-formula id="IE44"><mml:math id="IM46" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></inline-formula> and <italic toggle="yes">j</italic> is the patient index. These generated examples can be obtained by running a Markov chain to convergence using Gibbs sampling. However, in practice, the sampling process does not wait for convergence. Instead, the samples are obtained after 5-step Gibbs sampling in our case.</p>
      <p>Finally, the learning procedure in the ECMarker is as follows (<xref rid="btaa935-F1" ref-type="fig">Algorithm 1</xref>). First, initialize <inline-formula id="IE45"><mml:math id="IM47" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula id="IE46"><mml:math id="IM48" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>←</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:math></inline-formula> and <inline-formula id="IE47"><mml:math id="IM49" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>←</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi></mml:math></inline-formula>. At the learning iteration <inline-formula id="IE48"><mml:math id="IM50" display="inline" overflow="scroll"><mml:mi>t</mml:mi></mml:math></inline-formula>, let <inline-formula id="IE49"><mml:math id="IM51" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> be the model parameters. We generate <inline-formula id="IE50"><mml:math id="IM52" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msup><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula> using the Gibbs sampling. Then we update <inline-formula id="IE51"><mml:math id="IM53" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mo>η</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>Δ</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula>, where <inline-formula id="IE52"><mml:math id="IM54" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mo>η</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the learning rate and:&gt;
<disp-formula id="E9"><label>(7)</label><mml:math id="M9" display="block" overflow="scroll"><mml:mrow><mml:mo>Δ</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mo>Θ</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mo>≈</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:munder><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:munder><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mi>j</mml:mi><mml:mo>−</mml:mo></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mi>j</mml:mi><mml:mo>−</mml:mo></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mo>Θ</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
      <fig position="float" id="btaa935-F6">
        <graphic xlink:href="btaa935f6" position="float"/>
      </fig>
      <p>The convergence of the algorithm toward the local optimum (since the loss function is non-convex) depends on the optimizer. We used the stochastic gradient descent (SGD) (<xref rid="btaa935-B4" ref-type="bibr">Bottou, 2010</xref>) in ECMarker, which converges to a local minimum with an explicit convergence rate of <inline-formula id="IE53"><mml:math id="IM55" display="inline" overflow="scroll"><mml:mi>O</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>, where <italic toggle="yes">T</italic> is the number of iterations. After training the model, the updated matrix <inline-formula id="IE54"><mml:math id="IM56" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mo>Θ</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> can be used as an adjacency matrix to construct a gene network, revealing the gene-gene relationships for predicting phenotypes (e.g. disease stages) and providing potential novel mechanistic insights.</p>
    </sec>
    <sec>
      <title>2.3 Prioritization of the biomarker genes in ECMarker for phenotypes</title>
      <p>Once the ECMarker classification model is trained, we further used a derivative-based method called integrated gradient for prioritizing input features (e.g. genes) (<xref rid="btaa935-B66" ref-type="bibr">Sundararajan et al., 2017</xref>). In particular, we computed the gradient of model’s prediction with respect to each individual gene to show how the output response value (i.e. early versus late stages) changes with respect to a small change of input gene expression value. Hence, calculating these gradients for given input genes provide potential clues about which genes attribute the stage outcomes. This can be also interpreted to see which features are not selected due to <inline-formula id="IE55"><mml:math id="IM57" display="inline" overflow="scroll"><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:math></inline-formula> regularization since the gradients for these input genes are zeros. The output response value can be computed as the posterior class probability distribution given input <inline-formula id="IE96"><mml:math id="IM58" display="inline" overflow="scroll"><mml:mi>v</mml:mi></mml:math></inline-formula> and has the following closed form:
<disp-formula id="E10"><mml:math id="M10" display="block" overflow="scroll"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula id="IE57"><mml:math id="IM59" display="inline" overflow="scroll"><mml:mi>F</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the free energy over all phenotypes in the output layer as in <xref rid="E6" ref-type="disp-formula">Equation (5)</xref>, and <inline-formula id="IE58"><mml:math id="IM60" display="inline" overflow="scroll"><mml:mi>F</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula> is the free energy with regard to phenotype <inline-formula id="IE59"><mml:math id="IM61" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">y</mml:mi><mml:mo>=</mml:mo><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="normal"> </mml:mi><mml:mo>(</mml:mo><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi>K</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>, calculated as <inline-formula id="IE60"><mml:math id="IM62" display="inline" overflow="scroll"><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">a</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">v</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msup><mml:mi mathvariant="bold-italic">Lv</mml:mi><mml:mo>−</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mo> </mml:mo><mml:mtext>log</mml:mtext><mml:mo> </mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">v</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">U</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> The exact gradient of this probability distribution can be calculated using the <italic toggle="yes">autograd</italic> package in PyTorch (<xref rid="btaa935-B52" ref-type="bibr">Paszke et al., 2017</xref>). Furthermore, we define an importance score of each gene for the phenotype as the gradient of the gene to the phenotype. The higher positive scores that genes have, the more likely they contribute to predict the corresponded phenotype. Finally, given a phenotype, ECMarker prioritizes the genes for the phenotype via ranking its gene importance scores using the <italic toggle="yes">Captum</italic> package in PyTorch (<xref rid="btaa935-B6" ref-type="bibr">Kokhlikyan, 2020</xref>).</p>
    </sec>
    <sec>
      <title>2.4 Cancer gene expression and clinical datasets for building and testing ECMarker</title>
      <p>We built and tested the ECMarker with the following publicly accessible gene expression datasets in lung cancer. The Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset (<xref rid="btaa935-B13" ref-type="bibr">Gentles <italic toggle="yes">et al.</italic>, 2015</xref>) includes the log2-transformed gene expression data of 1103 non-small cell lung cancer (NSCLC) patients who had not received pre-biopsy treatment. We further imputed the missing values of the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset using the R package <italic toggle="yes">impute</italic> (<xref rid="btaa935-B69" ref-type="bibr">Trevor Hastie, 2020</xref>), and then standardized the data per sample; e.g. a mean of zero and a standard deviation of 1. Also, we grouped the patients based on their TMN stages, with (I + IA + IB) as the early stage (<italic toggle="yes">N</italic> = 766) and II, III and IV as the late stages (<italic toggle="yes">N</italic> = 337) and divided the dataset into balanced training and testing datasets via oversampling using the R package <italic toggle="yes">ROSE</italic> (<xref rid="btaa935-B43" ref-type="bibr">Lunardon <italic toggle="yes">et al.</italic>, 2014</xref>). The lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are two of the most common subtypes of NSCLC (<xref rid="btaa935-B17" ref-type="bibr">Herbst <italic toggle="yes">et al.</italic>, 2018</xref>). To demonstrate the utility of ECMarker in distinct subtypes of NSCLC, we downloaded the RNA-seq gene expression datasets (FPKM values) for the LUAD and LUSC patients in TCGA (<xref rid="btaa935-B67" ref-type="bibr">The Cancer Genome Atlas Research Network <italic toggle="yes">et al.</italic>, 2013</xref>), resulting in independent validation datasets TCGA-LUAD and TCGA-LUSC. Overall, we included 741 TCGA-LUAD patients (<italic toggle="yes">N</italic> = 409 and <italic toggle="yes">N</italic> = 332 in the early and late stages, respectively) and 758 TCGA-LUSC patients (<italic toggle="yes">N</italic> = 380 and <italic toggle="yes">N</italic> = 378 in the early and late stages, respectively) with (I + IA + IB) as the early stage and the rest as the late stage. A summary on the patient numbers of various stages is in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>.</p>
    </sec>
    <sec>
      <title>2.5 Identification of pathways and functions associated with early and late cancer stages via enrichment analysis</title>
      <p>We performed the enrichment analyses of the genes in the ECMarker for revealing underlying molecular mechanisms from genes to disease stages. In particular, given a phenotype (e.g. early stage), we applied the Gene Set Enrichment Analysis (GSEA) (<xref rid="btaa935-B65" ref-type="bibr">Subramanian et al., 2005</xref>) by a R package, <italic toggle="yes">fgsea</italic> (<xref rid="btaa935-B29" ref-type="bibr">Korotkevich <italic toggle="yes">et al.</italic>, 2019</xref>) to the ranking list of all input genes based on gene importance scores for the phenotype, and found the enriched terms including pathways, functions and oncogenic signatures from all eight gene sets of the Molecular Signatures Database (MSigDB) in the GSEA (<xref rid="btaa935-B36" ref-type="bibr">Liberzon <italic toggle="yes">et al.</italic>, 2011</xref>, <xref rid="btaa935-B35" ref-type="bibr">2015</xref>). Using this enrichment analysis, we identified the enriched terms for both early and late lung cancer stages, providing mechanistic insights in lung cancer progress.</p>
    </sec>
    <sec>
      <title>2.6 Survival analysis using ECMarker biomarker genes</title>
      <p>We used the R function, <italic toggle="yes">kmeans</italic> to partition the early cancer patients into two groups using the gene expression data of top early biomarker genes in ECMarker (<italic toggle="yes">N</italic> = 14). The survival analyses and Kaplan–Meier plots were implemented using the R package, <italic toggle="yes">survival</italic> (<xref rid="btaa935-B68" ref-type="bibr">Therneau, 2020</xref>).</p>
    </sec>
    <sec>
      <title>2.7 Gene network analysis in ECMarker</title>
      <p>The lateral connection weights (i.e. <italic toggle="yes">L</italic> matrix) from the ECMarker model how the gene-gene pairs (rather than individual genes) contribute to predict phenotypes, providing potentially additional mechanistic insights in terms of gene-gene relationships. Thus, using the <italic toggle="yes">L</italic> matrix as adjacency matrix, we further constructed a gene network from the ECMarker model for revealing potential gene regulatory relationships, especially on the transcription factors (TFs) to target genes (TGs). In addition, we compared the ECMarker gene network with the existing widely used methods such as GENIE3 (<xref rid="btaa935-B21" ref-type="bibr">Huynh-Thu <italic toggle="yes">et al.</italic>, 2010</xref>) that only predict gene regulatory networks (TFs to TGs) from gene expression data, without simultaneously predicting phenotypes like ECMarker. In particular, we calculated the pairwise cosine distances between same genes; i.e. a distance of <italic toggle="yes">i</italic>th row vectors of <inline-formula id="IE61"><mml:math id="IM63" display="inline" overflow="scroll"><mml:mi>L</mml:mi></mml:math></inline-formula> and <inline-formula id="IE62"><mml:math id="IM64" display="inline" overflow="scroll"><mml:mi>G</mml:mi></mml:math></inline-formula> for Gene <italic toggle="yes">i</italic>,
<disp-formula id="E11"><mml:math id="M11" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="⟨" close="⟩" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced open="∥" close="∥" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mfenced open="∥" close="∥" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi>m</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula>where <italic toggle="yes">G</italic> is the GENIE3’s adjacency matrix. The cosine distance ranges from 0 meaning exactly the same to 2 meaning exactly opposite. Actually, the cosine distances have been widely used to measure the similarity of vectors and matrices, revealing the structural equivalence of the same vertices (i.e. same gene) between two networks via calculating weighted common neighbors divided by the geometric mean of their degrees (<xref rid="btaa935-B61" ref-type="bibr">Salton, 1988</xref>). Furthermore, the cosine distance does not depend on the magnitude of the vector, which likely varies across different methods (e.g. ECMarker versus GENIE3) and thus is incomparable to each other. In contrast, the other distance metrics such as the Euclidean distance or correlation take in account for the vector/matrix magnitudes, so are not chosen here for evaluating comparison. We used the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset for comparing ECMarker and GENIE3.</p>
      <p>In addition to looking at the ECMarker network nodes and links, we also inferred the TF-TG relationships from the ECMarker network structures. In particular, we clustered the ECMarker gene network into a set of gene modules via hierarchical clustering (10 modules for the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset). The genes clustered together into a same module have strong connections for phenotype prediction, implying potential similar mechanisms such as co-regulation. Thus, we further identified the TFs with enriched target genes in each module (via TF binding sites on target gene regulatory regions) by g:Profiler (<xref rid="btaa935-B57" ref-type="bibr">Raudvere et al., 2019</xref>) and linked them to the modular target genes. Finally, we also calculated the centralities of the ECMarker gene network using <italic toggle="yes">igraph</italic> (Cs<bold>á</bold>rdi and Nepusz, <xref rid="btaa935-B8" ref-type="bibr">2006</xref>) and found the hub genes with high centrality (e.g. degree). Also, we applied ECMarker to the DREAM5 challenge data (Supporting Information). We found that ECMarker outperformed all other methods, including GENIE3, to infer the gene regulatory network in <italic toggle="yes">Saccharomyces cerevisiae</italic>. Since the <italic toggle="yes">S.cerevisiae</italic> network is the most complex in this DREAM5 challenge, this result demonstrates the ECMarker’s high performance for predicting gene regulatory networks in complex biological systems.</p>
    </sec>
    <sec>
      <title>2.8 Identification of drugs targeting biomarker genes predicted by ECMarker</title>
      <p>For discovering potential novel genome medicine using ECMarker, we identified the drugs targeting ECMarker biomarker genes of early and late cancer stages. In particular, we looked at a drug–gene database, GSCALite (<xref rid="btaa935-B38" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2018a</xref>, <xref rid="btaa935-B39" ref-type="bibr">b</xref>) that has calculated and summarized the <italic toggle="yes">z</italic>-scores of drug–gene pairs using the method in <xref rid="btaa935-B58" ref-type="bibr">Rees et al. (2016)</xref> for revealing the mechanisms of action (MoA) of drugs to the target genes. The drugs with high <italic toggle="yes">z</italic>-scores imply potential causal mechanistic effects such as activation mechanisms and direct protein targets to the genes (<xref rid="btaa935-B58" ref-type="bibr">Rees <italic toggle="yes">et al.</italic>, 2016</xref>). The <italic toggle="yes">z</italic>-scores were the Fisher’s <italic toggle="yes">z</italic>-transformed correlation coefficients between gene expression and drug sensitivity (IC50 value) across all possible cancer cell lines in the GDSC database (<xref rid="btaa935-B73" ref-type="bibr">Yang et al., 2012</xref>), and thus removed potential biased effects from specific tissue types corresponding to the cell lines. Given a phenotype (e.g. early cancer stage), we found a number of drugs for its ECMarker biomarker genes with high <italic toggle="yes">z</italic>-scores (FDR &lt; 0.05), suggesting their potential effects to the phenotype (e.g. early cancer drugs).</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <sec>
      <title>3.1 Lung cancer stage biomarker genes by ECMarker reveal functions on cancer development and progress</title>
      <p>We applied ECMaker to the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset (Section 2) for predicting the biomarker genes for lung cancer development and outcomes, especially for early-stage patients. In particular, we input the expression data of 10 102 genes from 766 early and 766 late patients (after balancing data) in the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset. After tuning hyperparameters in this ECMarker classification model, we had: (i) the input layer containing 10 102 genes; (ii) the hidden layer containing 9 hidden units; (ii) the output layer predicting early or late stage by a probability. Other hyperparameters were optimized as follows: train batch size = 50; learning rate = 0.1 and weight decay = 0.9 with the SGD method (<xref rid="btaa935-B4" ref-type="bibr">Bottou, 2010</xref>); <inline-formula id="IE63"><mml:math id="IM65" display="inline" overflow="scroll"><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:math></inline-formula> penalty parameter: 0.1; number of training epoch: 1. We also performed k = 10 cross-validation and found that the model has the consistent relatively high balanced accuracy values with Mean = <sub><bold>∼</bold></sub>0.74 and Variance =<sub><bold>∼</bold></sub> 0.001 compared to a baseline of 0.5 (for two phenotypes). Also, we applied another RBM-based model, elastic restricted Boltzmann machines (eRBMs) (<xref rid="btaa935-B76" ref-type="bibr">Zhang et al., 2017</xref>) that does not model lateral connections at the input layer, and found that its accuracy for predicting early and late stages is just around baseline of 0.5.</p>
      <p>After training and cross-validating models, we used the average predictive model to further calculate the gene importance scores for both early and late lung cancer stages (Section 2), and prioritized the stage biomarker genes (i.e. high importance scores) in the lung cancer (<xref rid="sup1" ref-type="supplementary-material">Supplementary File S1</xref>). As shown on <xref rid="btaa935-F2" ref-type="fig">Figure 2A</xref>, a number of known lung, immunity and cancer related pathways, especially on cancer development are significantly enriched among top early biomarker genes after gene set enrichment analyses (Section 2); e.g. the epithelial mesenchymal transition (EMT, <italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>6.2e-3) (<xref rid="btaa935-B40" ref-type="bibr">Lu and Kang, 2019</xref>), the gamma delta T cell activation (<italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>6.1e-3) (<xref rid="btaa935-B54" ref-type="bibr">Pauza <italic toggle="yes">et al.</italic>, 2018</xref>) and Interleukin-1 regulation (<italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>4.0e-3) (<xref rid="btaa935-B31" ref-type="bibr">Lewis <italic toggle="yes">et al.</italic>, 2006</xref>). Furthermore, top early and late genes are enriched with different upregulated pathways relating to lung cancer (<italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>0.001, <xref rid="btaa935-F2" ref-type="fig">Fig. 2B and C</xref>); e.g. lung cell differentiation and epithelium development are upregulated for the early stage, but lung cancer survival and differential markers are upregulated for the late stage. All enriched terms for early lung cancer stage are available in <xref rid="sup1" ref-type="supplementary-material">Supplementary File S2</xref>.</p>
      <fig position="float" id="btaa935-F2">
        <label>Fig. 2.</label>
        <caption>
          <p>Cancer-stage biomarker genes of ECMarker reveal the biological functions and pathways associated with lung cancer and cancer development. The enrichment analyses were accomplished by the GSEA for the ranked genes by gene importance scores for early or late lung cancer stages. (<bold>A</bold>) The upregulated functions and pathways significantly enriched in the early stage biomarker genes with <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.01. (<bold>B</bold>) and (<bold>C</bold>) Select functions and pathways associated with lung cancer and cancer development are up- or down-regulated at different stages</p>
        </caption>
        <graphic xlink:href="btaa935f2" position="float"/>
      </fig>
      <p>Lung cancer is also heterogeneous; e.g. non-small cell lung cancer has two major subtypes: adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) (<xref rid="btaa935-B41" ref-type="bibr">Lucchetta <italic toggle="yes">et al.</italic>, 2019</xref>). To test ECMarker for predicting the cancer stages in the lung cancer subtypes, we also applied ECMarker to the TCGA-LUAD and TCGA-LUSC gene expression datasets (Section 2). To obtain an appropriate sample size for training ECMarker as the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset, we combined TCGA-LUAD and TCGA-LUSC together and trained one ECMarker model for classifying four phenotypes: the LUAD early and late stages and the LUSC early and late stages, aiming to reveal the specific early cancer mechanisms to lung cancer subtypes. After training and testing, the model achieved a high classification accuracy of 0.48 compared to a baseline of 0.27 (for four phenotypes). Furthermore, we found that top early-stage biomarker genes for LUAD and LUSC have significantly anti-correlated importance scores (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>), suggesting potential distinct early cancer mechanisms across the lung cancer subtypes.</p>
    </sec>
    <sec>
      <title>3.2 ECMarker biomarker genes predict clinical outcomes for early lung cancer</title>
      <p>In addition to the genomic functions associated with cancer stages discovered by ECMarker, we also explored the relationships between stage biomarker genes and clinical outcomes of cancer patients. For example, we found that three lung cancer prognostic biomarker genes, CX3CR1, SLC15A2 and TFRC found by a recent multi-omics study (<xref rid="btaa935-B15" ref-type="bibr">Haghjoo <italic toggle="yes">et al.</italic>, 2020</xref>) also have very high ECMarker importance scores for early stage (&gt;80% genes). In addition, we found that the early lung cancer genes, SLC15A2 and TFRC are also hub genes (degree centrality in 1 and 10%) in the gene network revealed by ECMarker. To test the capability of ECMarker for predicting clinical outcomes for early cancer, we used top early-stage biomarkers learned by ECMarker (i.e. highest importance scores for early stage, Section 2) to partition the early cancer patients of Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> into two groups. We then found that two groups have significantly differential survival rates, suggesting that our ECMarker early biomarkers are able to predict early cancer survival rates (<italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>0.004, <xref rid="btaa935-F3" ref-type="fig">Fig. 3A</xref>). Furthermore, we validated the top ECMarker early biomarker genes using early patients in two independent cohorts, TCGA-LUAD and TCGA-LUSC, and found that the early patients groups clustered by these biomarkers also have significantly differential survival rates (<italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>0.0025, <xref rid="btaa935-F3" ref-type="fig">Fig. 3B and C</xref>). This demonstrates that our early biomarker genes have potential to predict survivals at the early cancer stage, suggesting the clinical interpretability of the ECMarker model.</p>
      <fig position="float" id="btaa935-F3">
        <label>Fig. 3.</label>
        <caption>
          <p>ECMarker stage biomarker genes predict early cancer survival rates. Early lung cancer patients were clustered into two groups (represented by two curves on each panel) based on the top 14 ECMarker biomarker genes for early stage lung cancer. These biomarker genes were found using the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset (<xref rid="btaa935-B13" ref-type="bibr">Gentles <italic toggle="yes">et al.</italic>, 2015</xref>). A Kaplan–Meier analysis showed that the early patient groups had significantly different survival rates (<italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.005) as shown in (<bold>A</bold>). In addition, application of these biomarker genes to an independent lung cancer cohorts, TCGA-LUAD and TCGA-LUSC (The Cancer Genome Atlas Research Network <italic toggle="yes">et al.</italic>, 2013), showed that the early-stage patients also had significantly different survival rates, as shown in (<bold>B</bold>) (TCGA-LUAD) and (<bold>C</bold>) (TCGA-LUSC) with <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.0025</p>
        </caption>
        <graphic xlink:href="btaa935f3" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>3.3 Gene network in the ECMarker uncovers gene regulatory mechanisms in lung cancer</title>
      <p>In addition to individual biomarker genes, we pursued the elucidation of the molecular mechanisms that drive the functional connectivity, especially in terms of gene regulation. Gene expression, though complex for phenotypes, is controlled by gene regulatory mechanisms. In particular, various regulatory factors, such as transcription factors (TFs), control the expression of biomarker genes to coordinate cancer phenotypes so they do not behave randomly (i.e. forming a GRN). ECMarker has the capability to model gene-gene interactions so that we could extract the weight values of lateral connections to describe the relationship of any pair of genes among the input genes. A larger weight value indicated a stronger connection between genes. According to this standard, we are able to extract the learned GRN from any well-trained ECMarker classification model (Section 2). Specifically using the ECMarker gene network learnt from the Gentles<xref rid="btaa935-B13" ref-type="bibr">2015</xref> dataset for predicting lung cancer stages, we found the subnetworks linking top early and late biomarker genes are different (<xref rid="btaa935-F4" ref-type="fig">Fig. 4A and B</xref>), suggesting potential developmental regulatory mechanisms in the lung cancer progress.</p>
      <fig position="float" id="btaa935-F4">
        <label>Fig. 4.</label>
        <caption>
          <p>The ECMarker gene network reveals the stage-specific gene connections and regulatory networks in the lung cancer. (<bold>A</bold>) The ECMarker gene network for early-stage biomarker genes (gene importance score &gt; 0.001 and top 100 links). (<bold>B</bold>) The ECMarker gene network for late-stage biomarker genes (gene importance score &gt; 0.001 and top 100 links). (<bold>C</bold>) A regulatory network among TFs inferred from the ECMarker gene network. The nodes are TF genes. The directed edges link TFs to the target genes (which are also TFs in this case). The node color corresponds to the degree centrality of TF in the network; e.g. skyblue represents high degree, and white means low degree. Note that all TFs shown here are predicted to associated with the lung cancer development from the ECMarker model</p>
        </caption>
        <graphic xlink:href="btaa935f4" position="float"/>
      </fig>
      <p>We found that a number of known TFs related to cancer development and oncogenes involve in the ECMarker gene network (from top 1% links), including 46 epithelial-to-mesenchymal transition (EMT) signature genes (<xref rid="btaa935-B5" ref-type="bibr">Byers <italic toggle="yes">et al.</italic>, 2013</xref>), lung cancer mutation genes (e.g. KRAS, BRAF, ALK, PIK3CA, AKT1, NRAS, EGFR, RET, ROS1) (<xref rid="btaa935-B27" ref-type="bibr">Khoo <italic toggle="yes">et al.</italic>, 2015</xref>) and the genes in the frequency of alterations and signaling pathways of the lung cancer [53 out of 83 such genes (<xref rid="btaa935-B33" ref-type="bibr">Li <italic toggle="yes">et al.</italic>, 2017</xref>)]. Moreover, a number of gene pairs from the top ECMarker links were also previously predicted to relate to the lung cancer gene regulation. For example, there are 2676 ECMarker top pairs (117 TF, 2348 TGs) also presented in a lung cancer regulatory network predicted by the one-class support vector machine (OC-SVM) model (<xref rid="btaa935-B74" ref-type="bibr">Zhang et al., 2018a</xref>, <xref rid="btaa935-B75" ref-type="bibr">b</xref>). Also, a recent study has identified 10 oncogenic TFs and 11 tumor suppressing genes potentially required for NSCLC cell proliferation (<xref rid="btaa935-B74" ref-type="bibr">Zhang et al., 2018a</xref>, <xref rid="btaa935-B75" ref-type="bibr">b</xref>). We found that all 10 such TFs and 10 out 11 suppressing genes in our top ECMarker links (involved in 1017 pairs). In addition, a previous correlation-based analysis focusing on microRNA targets in lung cancer also predicted a set of TFs and target genes for the NSCLC (<xref rid="btaa935-B45" ref-type="bibr">Mitra <italic toggle="yes">et al.</italic>, 2014</xref>), and was found to have 22 TFs, 101 target genes and 13 TF-TGs presenting in the top ECMarker links. Finally, we systematically compared the lung cancer networks of ECMarker and other computational methods such as GENIE3 that only use gene expression data to predict gene regulatory networks without integrating any phenotypic information (Section 2), especially on human diseases. Although ECMarker predicted a gene network specifically for predicting lung cancer development (i.e. stages), rather than generally for the lung cancer, there are still a variety of genes with high similarity between two networks (<italic toggle="yes">N</italic> = 1369 genes, 13.6% with cosine distance &lt; 0.35). This shows a consistency between ECMarker and GENIE3 but also implies that rest of the genes without high network similarity potentially relate to the specific developmental functions and pathways in lung cancer such as immune response, cell proliferation and differentiation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>).</p>
      <p>In addition to the ECMarker network nodes and links, using the network structures (e.g. gene modules), we also identified a list of TFs and TF-TG pairs for the lung cancer and cancer development (Section 2). In particular, we found a number of oncogenic TFs in our list, such as E2F genes, the cell-cycle TFs relating to tumor progression (<xref rid="btaa935-B25" ref-type="bibr">Johnson and Schneider-Broussard, 1998</xref>), and EGR genes, the TFs regulating multiple tumor suppressors (<xref rid="btaa935-B3" ref-type="bibr">Baron <italic toggle="yes">et al.</italic>, 2006</xref>). Furthermore, we identified a number of potential master regulators in lung cancer development using our network. For example, E2F-1, a well-known transcription factor promoting the tumor progression for many cancer types including lung cancer (<xref rid="btaa935-B11" ref-type="bibr">Engelmann and Putzer, 2012</xref>; <xref rid="btaa935-B74" ref-type="bibr">Zhang et al., 2018a</xref>, <xref rid="btaa935-B75" ref-type="bibr">b</xref>), plays a hub role (i.e. high degree) in the gene regulatory subnetwork in which target genes are TFs as well (<xref rid="btaa935-F4" ref-type="fig">Fig. 4C</xref>). Also, SP1, another known TF regulating lung cancer progression (<xref rid="btaa935-B19" ref-type="bibr">Hsu <italic toggle="yes">et al.</italic>, 2012</xref>) is in our network and also a hub gene. These hub genes in the ECMarker network imply that they regulate a number of lung cancer TFs as potential master regulators in lung cancer development. In addition, we found potential novel TFs for lung cancer development which were previously found to associate with other cancer types, such as WT1 for leukemia, kidney and prostate cancers (<xref rid="btaa935-B16" ref-type="bibr">Hastie, 2017</xref>) and MAZ, a MYC-associated zinc finger protein for pancreatic cancer (<xref rid="btaa935-B44" ref-type="bibr">Maity <italic toggle="yes">et al.</italic>, 2018</xref>). In addition, the target genes of some TFs are found to have significantly higher stage-specific importance scores than non-target genes (t-test <italic toggle="yes">P</italic><bold> </bold>&lt;<bold> </bold>0.05), suggesting that the cancer stage associated effects of the TFs; e.g. SP1 and AP-2 for late stage, TCF-1 and ER81 for early stage.</p>
    </sec>
    <sec>
      <title>3.4 ECMarker biomarker genes link to potential novel drugs for early lung cancer</title>
      <p>We further identified a number of drugs directly affecting ECMarker stage biomarker genes, aiming to provide potential novel candidates for early cancer medicine. Using the mechanisms of actions (MoAs) of drugs to genes (Section 2) (<xref rid="btaa935-B58" ref-type="bibr">Rees <italic toggle="yes">et al.</italic>, 2016</xref>), we identified a list of drugs for top 10 ECMarker early and late stage biomarker genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary File S3</xref>). As shown on <xref rid="btaa935-F5" ref-type="fig">Figure 5</xref>, the drugs and stage biomarker genes can be in general clustered into early and late groups, suggesting the stage-specific drug effects on lung cancer development. Our analyses revealed that several known drugs for lung cancer also have high effects to our stage biomarker genes; e.g. the Type I RAF inhibitor—Dabrafenib and the Type II RAF inhibitor—AZ628 for the treatment of non-V600 BRAF mutant lung cancer (<xref rid="btaa935-B48" ref-type="bibr">Noeparast <italic toggle="yes">et al.</italic>, 2018</xref>) in the late stage group, and YM155 for delaying the growth of NSCLC tumor xenografts is in the early stage group (<xref rid="btaa935-B22" ref-type="bibr">Iwasa <italic toggle="yes">et al.</italic>, 2008</xref>).</p>
      <fig position="float" id="btaa935-F5">
        <label>Fig. 5.</label>
        <caption>
          <p>ECMarker biomarker genes discover potentially novel effective drugs for early lung cancer. The heatmap shows the effective scores of drugs to genes in terms of the MoAs of drugs to genes (Section 2) (<xref rid="btaa935-B58" ref-type="bibr">Rees <italic toggle="yes">et al.</italic> 2016</xref>). The columns are the drugs with high MoAs to at least one of top 10 ECMarker stage biomarker genes. The rows are the genes from top 10 biomarker genes targeted by the drugs (blue: early stage, red: late stage)</p>
        </caption>
        <graphic xlink:href="btaa935f5" position="float"/>
      </fig>
      <p>Furthermore, several known drugs that were not originally used for lung cancer were predicted to have significant efforts on our early-stage biomarkers; e.g. Bortezomib (<xref rid="btaa935-B26" ref-type="bibr">Jones <italic toggle="yes">et al.</italic>, 2010</xref>), a proteasome inhibitor ameliorating breast cancer osteolytic disease, and AICAR inhibiting the cell growth in prostate cancer cells (<xref rid="btaa935-B10" ref-type="bibr">Digregorio <italic toggle="yes">et al.</italic>, 2019</xref>). In addition, TAK1 inhibitor 5Z-7-oxozeaenol for the treatment of cervical cancer is found to have potential effects on our late-stage lung cancer biomarkers (<xref rid="btaa935-B14" ref-type="bibr">Guan <italic toggle="yes">et al.</italic>, 2017</xref>). In addition, we observed that a few drugs previously used for multi-cancer or in clinical use for the late cancer stages are in the early stage group, suggesting their potential effects to the early lung cancer; e.g. CI-1040 and PD-0325901 for advanced non-small cell lung, breast, colon or pancreatic cancers (<xref rid="btaa935-B59" ref-type="bibr">Rinehart <italic toggle="yes">et al.</italic>, 2004</xref>). Another example is Ruxolitinib, a drug used during the Phase II study in the breast cancer (<xref rid="btaa935-B64" ref-type="bibr">Stover <italic toggle="yes">et al.</italic>, 2018</xref>) and also possibly for NSCLC patients in all-stage to enhance oncolytic virotherapy (<xref rid="btaa935-B53" ref-type="bibr">Patel <italic toggle="yes">et al.</italic>, 2019</xref>). Therefore, these drugs could potentially have effects on early cancer stages.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>ECMarker is an interpretable machine learning approach, built on the SRBM and DRBM for identifying gene expression biomarkers for disease phenotypes such as cancer stages. Beyond that a variety of machine learning methods typically pursuing the high prediction accuracy from genes to phenotypes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>), we demonstrated that the ECMarker model also has biologically and clinically interpretabilities, in addition to high accuracy; e.g. it revealed the underlying regulatory mechanisms during lung cancer development and the stage biomarker genes predicted the survival rates of early cancer patients. Also, we showed that the drugs targeting the ECMarker biomarker genes are potential novel candidates for early cancer medicine. These biomarker genes comprise novel molecular candidates for early cancer diagnosis and detection, and the gene networks could potentially guide future experimental validations for early cancer mechanisms and treatments. Furthermore, ECMarker is scalable for inputting all possible genes and implicitly selecting biomarker genes for phenotypes via neural network regularization, and thus does not need any prior feature selections. Although this study applied ECMarker to lung cancer data specifically, ECMarker is a general-purpose method and can therefore be applied for other cancer types (<xref rid="btaa935-B1" ref-type="bibr">Bailey <italic toggle="yes">et al.</italic>, 2018</xref>) and disease types such as neurodevelopmental and neurodegenerative diseases (<xref rid="btaa935-B9" ref-type="bibr">De Jager <italic toggle="yes">et al.</italic>, 2018</xref>; Li <italic toggle="yes">et al.</italic>, 2018).</p>
    <p>This study demonstrated that we are able to build the machine learning models that are biologically interpretable. This was our first round of attempts to address the lack of interpretability and translation of machine learning applications in biology and biomedicine. Given that cancer phenotypes are driven by a variety of multi-omic mechanisms (<xref rid="btaa935-B1" ref-type="bibr">Bailey <italic toggle="yes">et al.</italic>, 2018</xref>), including transcriptomics, epigenomics, metabolomics, etc., multi-omic data integration and analyses for understanding cancer biology have been emerging (<xref rid="btaa935-B56" ref-type="bibr">Rappoport and Shamir, 2019</xref>). Thus, we expect to develop advanced machine learning approaches that can reveal interactions across multi-omics relating to disease phenotypes in the near future; e.g. via multiview learning approaches (<xref rid="btaa935-B47" ref-type="bibr">Nguyen and Wang, 2020</xref>). In particular, by integrating genotyping data, ECMarker can be extended to a deep hierarchical model, similar to deep neural network models (<xref rid="btaa935-B70" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2018</xref>), to predict genotype-phenotype relationships and use intermediate biological connectivity and structures inside the model to reveal possible molecular mechanisms from genotype to phenotype.</p>
    <p>The present study focused on gene expression data at the individual tissue level. However, the cancer tissues consist of different cell types with various fitness and mutational profiles (<xref rid="btaa935-B60" ref-type="bibr">Saadatpour <italic toggle="yes">et al.</italic>, 2015</xref>). The continuous development of single-cell genomic and transcriptomic analyses for cancer research will enable us to explore how single cells contribute to cancer tissue expression and eventually affect phenotypes; e.g. single-cell deconvolution to estimate cell-type fractions (<xref rid="btaa935-B2" ref-type="bibr">Baron <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="btaa935-B71" ref-type="bibr">Wang <italic toggle="yes">et al.</italic>, 2019</xref>). Integrating single-cell data into the interpretable machine learning modeling and drug association analysis might uncover novel biological mechanisms and targetable key regulators at the cellular resolution for the advancement of precision cancer medicine.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btaa935_Supplementary_Data</label>
      <media xlink:href="btaa935_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>The authors thank Mr. Mufang Ying for helping <xref rid="btaa935-F4" ref-type="fig">Figure 4</xref>.</p>
    <sec>
      <title>Funding</title>
      <p>This work was supported by the grants of National Institutes of Health, R01AG067025, R21CA237955 and U01MH116492 to Daifeng Wang and U54HD090256 to Waisman Center at UW-Madison.</p>
      <p><italic toggle="yes">Conflict of Interest</italic>: none declared.</p>
    </sec>
  </ack>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btaa935-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailey</surname><given-names>M.H.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>Comprehensive characterization of cancer driver genes and mutations</article-title>. <source>Cell</source>, <volume>174</volume>, <fpage>1034</fpage>–<lpage>1035</lpage>.<pub-id pub-id-type="pmid">30096302</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baron</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2016</year>) 
<article-title>A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure</article-title>. <source>Cell Syst</source>., <volume>3</volume>, <fpage>346</fpage>–<lpage>360</lpage>.e344.<pub-id pub-id-type="pmid">27667365</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baron</surname><given-names>V.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2006</year>) 
<article-title>The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin</article-title>. <source>Cancer Gene Ther</source>., <volume>13</volume>, <fpage>115</fpage>–<lpage>124</lpage>.<pub-id pub-id-type="pmid">16138117</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B4">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Bottou</surname><given-names>L.</given-names></string-name></person-group> (<year>2010</year>) <source>Large-Scale Machine Learning with Stochastic Gradient Descent</source>. 
<publisher-name>Physica-Verlag HD</publisher-name>, 
<publisher-loc>Heidelberg</publisher-loc>, pp. <fpage>177</fpage>–<lpage>186</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byers</surname><given-names>L.A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2013</year>) 
<article-title>An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</article-title>. <source>Clin. Cancer Res</source>., <volume>19</volume>, <fpage>279</fpage>–<lpage>290</lpage>.<pub-id pub-id-type="pmid">23091115</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarke</surname><given-names>R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2008</year>) 
<article-title>The properties of high-dimensional data spaces: implications for exploring gene and protein expression data</article-title>. <source>Nat. Rev. Cancer</source>, <volume>8</volume>, <fpage>37</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">18097463</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Csárdi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Nepusz</surname><given-names>T.</given-names></string-name></person-group> (<year>2006</year>) The igraph software package for complex network research. <source>InterJournal, Complex Systems</source>, <volume>1695</volume>, <fpage>1</fpage>–<lpage>9</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Jager</surname><given-names>P.L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research</article-title>. <source>Sci. Data</source>, <volume>5</volume>, <fpage>180142</fpage>.<pub-id pub-id-type="pmid">30084846</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Digregorio</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) 
<article-title>Relevance of translation initiation in diffuse glioma biology and its therapeutic potential</article-title>. <source>Cells</source>, <volume>8</volume>, <fpage>1542</fpage>.<pub-id pub-id-type="pmid">31795417</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Engelmann</surname><given-names>D.</given-names></string-name>, <string-name><surname>Putzer</surname><given-names>B.M.</given-names></string-name></person-group> (<year>2012</year>) 
<article-title>The dark side of E2F1: in transit beyond apoptosis</article-title>. <source>Cancer Res</source>., <volume>72</volume>, <fpage>571</fpage>–<lpage>575</lpage>.<pub-id pub-id-type="pmid">22298593</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frost</surname><given-names>J.K.</given-names></string-name></person-group>  <etal>et al</etal> (<year>1984</year>) 
<article-title>Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study</article-title>. <source>Am. Rev. Respir. Dis</source>., <volume>130</volume>, <fpage>549</fpage>–<lpage>554</lpage>.<pub-id pub-id-type="pmid">6091505</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gentles</surname><given-names>A.J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) 
<article-title>Integrating tumor and stromal gene expression signatures with clinical indices for survival stratification of early-stage non-small cell lung cancer</article-title>. <source>JNCI J. Natl. Cancer Inst</source>., <volume>107</volume>, <fpage>djv211</fpage>.<pub-id pub-id-type="pmid">26286589</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guan</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) 
<article-title>TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis</article-title>. <source>Oncotarget</source>, <volume>8</volume>, <fpage>33666</fpage>–<lpage>33675</lpage>.<pub-id pub-id-type="pmid">28430599</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haghjoo</surname><given-names>N.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2020</year>) 
<article-title>Introducing a panel for early detection of lung adenocarcinoma by using data integration of genomics, epigenomics, transcriptomics and proteomics</article-title>. <source>Exp. Mol. Pathol</source>., <volume>112</volume>, <fpage>104360</fpage>.<pub-id pub-id-type="pmid">31843580</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hastie</surname><given-names>N.D.</given-names></string-name></person-group> (<year>2017</year>) 
<article-title>Wilms' tumour 1 (WT1) in development, homeostasis and disease</article-title>. <source>Development</source>, <volume>144</volume>, <fpage>2862</fpage>–<lpage>2872</lpage>.<pub-id pub-id-type="pmid">28811308</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Herbst</surname><given-names>R.S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>The biology and management of non-small cell lung cancer</article-title>. <source>Nature</source>, <volume>553</volume>, <fpage>446</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">29364287</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hinton</surname><given-names>G.E.</given-names></string-name>, <string-name><surname>Salakhutdinov</surname><given-names>R.R.</given-names></string-name></person-group> (<year>2006</year>) 
<article-title>Reducing the dimensionality of data with neural networks</article-title>. <source>Science</source>, <volume>313</volume>, <fpage>504</fpage>–<lpage>507</lpage>.<pub-id pub-id-type="pmid">16873662</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsu</surname><given-names>T.I.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2012</year>) 
<article-title>Sp1 expression regulates lung tumor progression</article-title>. <source>Oncogene</source>, <volume>31</volume>, <fpage>3973</fpage>–<lpage>3988</lpage>.<pub-id pub-id-type="pmid">22158040</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname><given-names>Z.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2008</year>) 
<article-title>Genetic variants of miRNA sequences and non-small cell lung cancer survival</article-title>. <source>J. Clin. Invest</source>., <volume>118</volume>, <fpage>2600</fpage>–<lpage>2608</lpage>.<pub-id pub-id-type="pmid">18521189</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huynh-Thu</surname><given-names>V.A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2010</year>) 
<article-title>Inferring regulatory networks from expression data using tree-based methods</article-title>. <source>PLoS One</source>, <volume>5</volume>, <fpage>e12776</fpage>.<pub-id pub-id-type="pmid">20927193</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iwasa</surname><given-names>T.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2008</year>) 
<article-title>Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines</article-title>. <source>Clin. Cancer Res</source>., <volume>14</volume>, <fpage>6496</fpage>–<lpage>6504</lpage>.<pub-id pub-id-type="pmid">18927289</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iyer</surname><given-names>A.S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) 
<article-title>Computational methods to dissect gene regulatory networks in cancer</article-title>. <source>Curr. Opin. Syst. Biol</source>., <volume>2</volume>, <fpage>115</fpage>–<lpage>122</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jagga</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>D.</given-names></string-name></person-group> (<year>2014</year>) 
<article-title>Classification models for clear cell renal carcinoma stage progression, based on tumor RNAseq expression trained supervised machine learning algorithms</article-title>. <source>BMC Proc</source>., <volume>8</volume>, <fpage>S2</fpage>–<lpage>S2</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname><given-names>D.G.</given-names></string-name>, <string-name><surname>Schneider-Broussard</surname><given-names>R.</given-names></string-name></person-group> (<year>1998</year>) 
<article-title>Role of E2F in cell cycle control and cancer</article-title>. <source>Front. Biosci</source>., <volume>3</volume>, <fpage>d447</fpage>–<lpage>d448</lpage>.<pub-id pub-id-type="pmid">9556498</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jones</surname><given-names>M.D.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2010</year>) 
<article-title>A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes</article-title>. <source>Clin. Cancer Res</source>., <volume>16</volume>, <fpage>4978</fpage>–<lpage>4989</lpage>.<pub-id pub-id-type="pmid">20843837</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khoo</surname><given-names>C.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) 
<article-title>Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond</article-title>. <source>Transl. Lung Cancer Res</source>., <volume>4</volume>, <fpage>126</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">25870795</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeffler</surname><given-names>H.P.</given-names></string-name></person-group>  <etal>et al</etal> (<year>1991</year>) 
<article-title>Molecular mechanisms of cancer</article-title>. <source>West. J. Med</source>., <volume>155</volume>, <fpage>505</fpage>–<lpage>514</lpage>.<pub-id pub-id-type="pmid">1815390</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B6">
      <mixed-citation publication-type="journal">Kokhlikyan,N. et al. (2020) Captum: a unified and generic model interpretability library for pytorch. arXiv PreprintarXiv : 2009.07896.</mixed-citation>
    </ref>
    <ref id="btaa935-B29">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Korotkevich</surname><given-names>G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) Fast gene set enrichment analysis. <italic toggle="yes"><italic toggle="yes">bioRxiv</italic>. doi: 10.1101/060012.</italic></mixed-citation>
    </ref>
    <ref id="btaa935-B30">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Larochelle</surname><given-names>H.</given-names></string-name>, <string-name><surname>Bengio</surname><given-names>Y.</given-names></string-name></person-group> (<year>2008</year>) Classification using discriminative restricted Boltzmann machines. In <italic toggle="yes">Proceedings of the 25th International Conference on Machine learning</italic>. Association for Computing Machinery, Helsinki, Finland. pp. <fpage>536</fpage>–<lpage>543</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lewis</surname><given-names>A.M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2006</year>) 
<article-title>Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment</article-title>. <source>J. Transl. Med</source>., <volume>4</volume>, <fpage>48</fpage>.<pub-id pub-id-type="pmid">17096856</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal>; BrainSpan Consortium. (<year>2018</year>) 
<article-title>Integrative functional genomic analysis of human brain development and neuropsychiatric risks</article-title>. <source>Science</source>, <volume>362</volume>, <fpage>eaat7615</fpage>.<pub-id pub-id-type="pmid">30545854</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Z.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) 
<article-title>The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies</article-title>. <source>Nat. Commun</source>., <volume>8</volume>, <fpage>14356</fpage>.<pub-id pub-id-type="pmid">28205554</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Libbrecht</surname><given-names>M.W.</given-names></string-name>, <string-name><surname>Noble</surname><given-names>W.S.</given-names></string-name></person-group> (<year>2015</year>) 
<article-title>Machine learning applications in genetics and genomics</article-title>. <source>Nat. Rev. Genet</source>., <volume>16</volume>, <fpage>321</fpage>–<lpage>332</lpage>.<pub-id pub-id-type="pmid">25948244</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) 
<article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source>Cell Syst</source>., <volume>1</volume>, <fpage>417</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">26771021</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2011</year>) 
<article-title>Molecular signatures database (MSigDB) 3.0</article-title>. <source>Bioinformatics</source>, <volume>27</volume>, <fpage>1739</fpage>–<lpage>1740</lpage>.<pub-id pub-id-type="pmid">21546393</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindeman</surname><given-names>N.I.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2013</year>) 
<article-title>Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology</article-title>. <source>J. Thorac. Oncol</source>., <volume>8</volume>, <fpage>823</fpage>–<lpage>859</lpage>.<pub-id pub-id-type="pmid">23552377</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>C.J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>a) 
<article-title>GSCALite: a web server for gene set cancer analysis</article-title>. <source>Bioinformatics</source>, <volume>34</volume>, <fpage>3771</fpage>–<lpage>3772</lpage>.<pub-id pub-id-type="pmid">29790900</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>b) 
<article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title>. <source>Cell</source>, <volume>173</volume>, <fpage>400</fpage>–<lpage>416</lpage>.e411.<pub-id pub-id-type="pmid">29625055</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Kang</surname><given-names>Y.</given-names></string-name></person-group> (<year>2019</year>) 
<article-title>Epithelial-mesenchymal plasticity in cancer progression and metastasis</article-title>. <source>Dev. Cell</source>, <volume>49</volume>, <fpage>361</fpage>–<lpage>374</lpage>.<pub-id pub-id-type="pmid">31063755</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lucchetta</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) 
<article-title>Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response</article-title>. <source>BMC Cancer</source>, <volume>19</volume>, <fpage>824</fpage>.<pub-id pub-id-type="pmid">31429720</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ludwig</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name></person-group> (<year>2005</year>) 
<article-title>Biomarkers in cancer staging, prognosis and treatment selection</article-title>. <source>Nat. Rev. Cancer</source>, <volume>5</volume>, <fpage>845</fpage>–<lpage>856</lpage>.<pub-id pub-id-type="pmid">16239904</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lunardon</surname><given-names>N.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) 
<article-title>ROSE: a package for binary imbalanced learning</article-title>. <source>R. J</source>., <volume>6</volume>, <fpage>79</fpage>–<lpage>89</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maity</surname><given-names>G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling</article-title>. <source>J. Biol. Chem</source>., <volume>293</volume>, <fpage>4334</fpage>–<lpage>4349</lpage>.<pub-id pub-id-type="pmid">29414775</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitra</surname><given-names>R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) 
<article-title>Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer</article-title>. <source>RNA</source>, <volume>20</volume>, <fpage>1356</fpage>–<lpage>1368</lpage>.<pub-id pub-id-type="pmid">25024357</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B46">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Molina</surname><given-names>J.R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2008</year>) 
<article-title>Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</article-title>. <source>Mayo Clin. Proc</source>., <volume>83</volume>, <fpage>584</fpage>–<lpage>594</lpage>.<pub-id pub-id-type="pmid">18452692</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname><given-names>N.D.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D.</given-names></string-name></person-group> (<year>2020</year>) 
<article-title>Multiview learning for understanding functional multiomics</article-title>. <source>PLoS Comput. Biol</source>., <volume>16</volume>, <fpage>e1007677</fpage>.<pub-id pub-id-type="pmid">32240163</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noeparast</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer</article-title>. <source>Oncotarget</source>, <volume>9</volume>, <fpage>16110</fpage>–<lpage>16123</lpage>.<pub-id pub-id-type="pmid">29662630</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B49">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Osindero</surname><given-names>S.</given-names></string-name>, <string-name><surname>Hinton</surname><given-names>G.</given-names></string-name></person-group> (<year>2007</year>) Modeling image patches with a directed hierarchy of Markov random fields. In <italic toggle="yes">Proceedings of the 20th International Conference on Neural Information Processing Systems</italic>. 
<publisher-name>Curran Associates Inc</publisher-name>., 
<publisher-loc>Vancouver, British Columbia, Canada</publisher-loc>. pp. <fpage>1121</fpage>–<lpage>1128</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paik</surname><given-names>P.K.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2011</year>) 
<article-title>Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations</article-title>. <source>J. Clin. Oncol</source>., <volume>29</volume>, <fpage>2046</fpage>–<lpage>2051</lpage>.<pub-id pub-id-type="pmid">21483012</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pao</surname><given-names>W.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2004</year>) 
<article-title>EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>101</volume>, <fpage>13306</fpage>–<lpage>13311</lpage>.<pub-id pub-id-type="pmid">15329413</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B52">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Paszke</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) Automatic Differentiation in PyTorch. 31st Conference on Neural Information Processing Systems (NIPS 2017), Long Beach, CA, USA</mixed-citation>
    </ref>
    <ref id="btaa935-B53">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>M.R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) 
<article-title>JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models</article-title>. <source>Cancer Gene Ther</source>., <volume>26</volume>, <fpage>411</fpage>–<lpage>418</lpage>.<pub-id pub-id-type="pmid">30622322</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B54">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pauza</surname><given-names>C.D.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>Gamma delta T cell therapy for cancer: it is good to be local</article-title>. <source>Front Immunol</source>, <volume>9</volume>, <fpage>1305</fpage>.<pub-id pub-id-type="pmid">29937769</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B55">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rahimi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gönen</surname><given-names>M.</given-names></string-name></person-group> (<year>2018</year>) 
<article-title>Discriminating early- and late-stage cancers using multiple kernel learning on gene sets</article-title>. <source>Bioinformatics</source>, <volume>34</volume>, <fpage>i412</fpage>–<lpage>i421</lpage>.<pub-id pub-id-type="pmid">29949993</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B56">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rappoport</surname><given-names>N.</given-names></string-name>, <string-name><surname>Shamir</surname><given-names>R.</given-names></string-name></person-group> (<year>2019</year>) 
<article-title>Multi-omic and multi-view clustering algorithms: review and cancer benchmark</article-title>. <source>Nucleic Acids Res</source>., <volume>47</volume>, <fpage>1044</fpage>–<lpage>1044</lpage>.<pub-id pub-id-type="pmid">30496480</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B57">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raudvere</surname><given-names>U.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) 
<article-title>g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)</article-title>. <source>Nucleic Acids Res</source>., <volume>47</volume>, <fpage>W191</fpage>–<lpage>W198</lpage>.<pub-id pub-id-type="pmid">31066453</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B58">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname><given-names>M.G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2016</year>) 
<article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>. <source>Nat. Chem. Biol</source>., <volume>12</volume>, <fpage>109</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">26656090</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B59">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rinehart</surname><given-names>J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2004</year>) 
<article-title>Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer</article-title>. <source>J. Clin. Oncol</source>., <volume>22</volume>, <fpage>4456</fpage>–<lpage>4462</lpage>.<pub-id pub-id-type="pmid">15483017</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B60">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saadatpour</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) 
<article-title>Single-cell analysis in cancer genomics</article-title>. <source>Trends Genet</source>., <volume>31</volume>, <fpage>576</fpage>–<lpage>586</lpage>.<pub-id pub-id-type="pmid">26450340</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B61">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Salton</surname><given-names>G.</given-names></string-name></person-group> (<year>1988</year>) <source>Automatic Text Processing: The Transformation, Analysis, and Retrieval of Information by Computer</source>. 
<publisher-name>Addison-Wesley</publisher-name>, 
<publisher-loc>Reading, Mass</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="btaa935-B62">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname><given-names>R.L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>Cancer statistics, 2018</article-title>. <source>CA Cancer J. Clin</source>., <volume>68</volume>, <fpage>7</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">29313949</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B63">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Statnikov</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2008</year>) 
<article-title>A comprehensive comparison of random forests and support vector machines for microarray-based cancer classification</article-title>. <source>BMC Bioinformatics</source>, <volume>9</volume>, <fpage>319</fpage>.<pub-id pub-id-type="pmid">18647401</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B64">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stover</surname><given-names>D.G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer</article-title>. <source>NPJ Breast Cancer</source>, <volume>4</volume>, <fpage>10</fpage>.<pub-id pub-id-type="pmid">29761158</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B65">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2005</year>) 
<article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>102</volume>, <fpage>15545</fpage>–<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B66">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Sundararajan</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) Axiomatic attribution for deep networks. In <italic toggle="yes">Proceedings of the 34th International Conference on Machine Learning – Volume</italic> 70. JMLR.org, Sydney, NSW, Australia. pp. <fpage>3319</fpage>–<lpage>3328</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa935-B67">
      <mixed-citation publication-type="journal">The Cancer Genome Atlas Research Network <etal>et al</etal> (<year>2013</year>) 
<article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat. Genet</source>., <volume>45</volume>, <fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B68">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Therneau</surname><given-names>T.M.</given-names></string-name></person-group> (<year>2020</year>) A Package for Survival Analysis in R. R package version 3.2-7. <ext-link xlink:href="https://CRAN.R-project.org/package=survival" ext-link-type="uri">https://CRAN.R-project.org/package=survival, (28 September 2020, date last accessed).</ext-link></mixed-citation>
    </ref>
    <ref id="btaa935-B69">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Trevor Hastie</surname><given-names>R.T.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2020</year>) impute: impute: Imputation for microarray data. Bioconductor. R package version 1.62.0.</mixed-citation>
    </ref>
    <ref id="btaa935-B70">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>D.</given-names></string-name></person-group>  <etal>et al</etal>; PsychENCODE Consortium. (<year>2018</year>) 
<article-title>Comprehensive functional genomic resource and integrative model for the human brain</article-title>. <source>Science</source>, <volume>362</volume>, <fpage>eaat8464</fpage>.<pub-id pub-id-type="pmid">30545857</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B71">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) 
<article-title>Bulk tissue cell type deconvolution with multi-subject single-cell expression reference</article-title>. <source>Nat. Commun</source>., <volume>10</volume>, <fpage>380</fpage>.<pub-id pub-id-type="pmid">30670690</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B72">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname><given-names>Y.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) 
<article-title>A deep learning-based multi-model ensemble method for cancer prediction</article-title>. <source>Comput. Methods Programs Biomed</source>., <volume>153</volume>, <fpage>1</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29157442</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B73">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>W.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2012</year>) 
<article-title>Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source>Nucleic Acids Res</source>., <volume>41</volume>, <fpage>D955</fpage>–<lpage>D961</lpage>.<pub-id pub-id-type="pmid">23180760</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B74">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>D.L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>a) 
<article-title>Genome-wide identification of transcription factors that are critical to non-small cell lung cancer</article-title>. <source>Cancer Lett</source>., <volume>434</volume>, <fpage>132</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">30031117</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B75">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>b) 
<article-title>Landscape of transcriptional deregulation in lung cancer</article-title>. <source>BMC Genomics</source>, <volume>19</volume>, <fpage>435</fpage>.<pub-id pub-id-type="pmid">29866045</pub-id></mixed-citation>
    </ref>
    <ref id="btaa935-B76">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) 
<article-title>Elastic restricted Boltzmann machines for cancer data analysis</article-title>. <source>Quant. Biol</source>., <volume>5</volume>, <fpage>159</fpage>–<lpage>172</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
